Cargando…
Risk prediction in medically treated chronic thromboembolic pulmonary hypertension
BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective regist...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056726/ https://www.ncbi.nlm.nih.gov/pubmed/33879094 http://dx.doi.org/10.1186/s12890-021-01495-6 |
_version_ | 1783680707187441664 |
---|---|
author | Quan, Ruilin Yang, Yuanhua Yang, Zhenwen Tian, Hongyan Li, Shengqing Shen, Jieyan Ji, Yingqun Zhang, Gangcheng Zhang, Caojin Wang, Guangyi Liu, Yuhao Cheng, Zhaozhong Yu, Zaixin Song, Zhiyuan Zheng, Zeqi Cui, Wei Chen, Yucheng Liu, Shuang Chen, Xiaoxi Qian, Yuling Xiong, Changming Shan, Guangliang He, Jianguo |
author_facet | Quan, Ruilin Yang, Yuanhua Yang, Zhenwen Tian, Hongyan Li, Shengqing Shen, Jieyan Ji, Yingqun Zhang, Gangcheng Zhang, Caojin Wang, Guangyi Liu, Yuhao Cheng, Zhaozhong Yu, Zaixin Song, Zhiyuan Zheng, Zeqi Cui, Wei Chen, Yucheng Liu, Shuang Chen, Xiaoxi Qian, Yuling Xiong, Changming Shan, Guangliang He, Jianguo |
author_sort | Quan, Ruilin |
collection | PubMed |
description | BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective registry study from August 2009 to July 2018. A multivariable Cox proportional hazards model was utilized to derive the prognostic model, and a simplified risk score was created thereafter. Model performance was evaluated in terms of discrimination and calibration, and compared to the Swedish/COMPERA risk stratification method. Internal and external validation were conducted to validate the model performance. RESULTS: A total of 432 patients were enrolled. During a median follow-up time of 38.73 months (IQR: 20.79, 66.10), 94 patients (21.8%) died. The 1-, 3-, and 5-year survival estimates were 95.5%, 83.7%, and 70.9%, respectively. The final model included the following variables: the Swedish/COMPERA risk stratum (low-, intermediate- or high-risk stratum), pulmonary vascular resistance (PVR, ≤ or > 1600 dyn·s/cm(5)), total bilirubin (TBIL, ≤ or > 38 µmol/L) and chronic kidney disease (CKD, no or yes). Compared with the Swedish/COMPERA risk stratification method alone, both the derived model [C-index: 0.715; net reclassification improvement (NRI): 0.300; integrated discriminatory index (IDI): 0.095] and the risk score (C-index: 0.713; NRI: 0.300; IDI: 0.093) showed improved discriminatory power. The performance was validated in a validation cohort of 84 patients (C-index = 0.707 for the model and 0.721 for the risk score). CONCLUSIONS: A novel risk stratification strategy can serve as a useful tool for determining prognosis and guide management for medically treated CTEPH patients. Trial registration: ClinicalTrials.gov (Identifier: NCT01417338). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01495-6. |
format | Online Article Text |
id | pubmed-8056726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80567262021-04-21 Risk prediction in medically treated chronic thromboembolic pulmonary hypertension Quan, Ruilin Yang, Yuanhua Yang, Zhenwen Tian, Hongyan Li, Shengqing Shen, Jieyan Ji, Yingqun Zhang, Gangcheng Zhang, Caojin Wang, Guangyi Liu, Yuhao Cheng, Zhaozhong Yu, Zaixin Song, Zhiyuan Zheng, Zeqi Cui, Wei Chen, Yucheng Liu, Shuang Chen, Xiaoxi Qian, Yuling Xiong, Changming Shan, Guangliang He, Jianguo BMC Pulm Med Research Article BACKGROUND: At present, there is no generally accepted comprehensive prognostic risk prediction model for medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients. METHODS: Consecutive medically treated CTEPH patients were enrolled in a national multicenter prospective registry study from August 2009 to July 2018. A multivariable Cox proportional hazards model was utilized to derive the prognostic model, and a simplified risk score was created thereafter. Model performance was evaluated in terms of discrimination and calibration, and compared to the Swedish/COMPERA risk stratification method. Internal and external validation were conducted to validate the model performance. RESULTS: A total of 432 patients were enrolled. During a median follow-up time of 38.73 months (IQR: 20.79, 66.10), 94 patients (21.8%) died. The 1-, 3-, and 5-year survival estimates were 95.5%, 83.7%, and 70.9%, respectively. The final model included the following variables: the Swedish/COMPERA risk stratum (low-, intermediate- or high-risk stratum), pulmonary vascular resistance (PVR, ≤ or > 1600 dyn·s/cm(5)), total bilirubin (TBIL, ≤ or > 38 µmol/L) and chronic kidney disease (CKD, no or yes). Compared with the Swedish/COMPERA risk stratification method alone, both the derived model [C-index: 0.715; net reclassification improvement (NRI): 0.300; integrated discriminatory index (IDI): 0.095] and the risk score (C-index: 0.713; NRI: 0.300; IDI: 0.093) showed improved discriminatory power. The performance was validated in a validation cohort of 84 patients (C-index = 0.707 for the model and 0.721 for the risk score). CONCLUSIONS: A novel risk stratification strategy can serve as a useful tool for determining prognosis and guide management for medically treated CTEPH patients. Trial registration: ClinicalTrials.gov (Identifier: NCT01417338). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01495-6. BioMed Central 2021-04-20 /pmc/articles/PMC8056726/ /pubmed/33879094 http://dx.doi.org/10.1186/s12890-021-01495-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Quan, Ruilin Yang, Yuanhua Yang, Zhenwen Tian, Hongyan Li, Shengqing Shen, Jieyan Ji, Yingqun Zhang, Gangcheng Zhang, Caojin Wang, Guangyi Liu, Yuhao Cheng, Zhaozhong Yu, Zaixin Song, Zhiyuan Zheng, Zeqi Cui, Wei Chen, Yucheng Liu, Shuang Chen, Xiaoxi Qian, Yuling Xiong, Changming Shan, Guangliang He, Jianguo Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title | Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title_full | Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title_fullStr | Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title_full_unstemmed | Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title_short | Risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
title_sort | risk prediction in medically treated chronic thromboembolic pulmonary hypertension |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056726/ https://www.ncbi.nlm.nih.gov/pubmed/33879094 http://dx.doi.org/10.1186/s12890-021-01495-6 |
work_keys_str_mv | AT quanruilin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT yangyuanhua riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT yangzhenwen riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT tianhongyan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT lishengqing riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT shenjieyan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT jiyingqun riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT zhanggangcheng riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT zhangcaojin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT wangguangyi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT liuyuhao riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT chengzhaozhong riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT yuzaixin riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT songzhiyuan riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT zhengzeqi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT cuiwei riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT chenyucheng riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT liushuang riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT chenxiaoxi riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT qianyuling riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT xiongchangming riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT shanguangliang riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension AT hejianguo riskpredictioninmedicallytreatedchronicthromboembolicpulmonaryhypertension |